BioSpace News Archive

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2018.

ITUS Corporation (NASDAQ: ITUS) today announced that it and its research partner, Moffitt Cancer Center, have requested a meeting with the US FDA to review the plan for advancing their CAR-T therapy for Ovarian Cancer into human clinical trials.

Company co-founder Mitch Finer named new Chairman of the Board

Presented Data from Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Overall Response Rate of 83% and Durable Ongoing Reponses up to 22 Months

REGENXBIO Inc. announced that it will host a conference call on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights.

Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).

TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study and Successful Dialogues with FDA and EMA

Conference call scheduled today at 9:00 a.m. ET

AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston.